Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00436917 · ClinicalTrials.gov registry record · NA

Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

A NA study of Breast Cancer and Osteoporosis, sponsored by Mayo Clinic.

Completed
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT00436917: Completed NA study of Breast Cancer and Osteoporosis, sponsored by Mayo Clinic.

NCT00436917 is a NA study of Breast Cancer and Osteoporosis that has completed, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00436917, a NA study of Breast Cancer and Osteoporosis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women receiving letrozole for stage I, stage II, or stage IIIA primary breast cancer.

Primary Outcome

Change: BMD values at twelve months post study entry minus BMD values at baseline, expressed as a percentage of the baseline value.

Interventions

  • DRUG zoledronic acid
  • PROCEDURE Letrozole as adjuvant therapy

Study Locations (2)

Florida

  • Mayo Clinic in Florida - Jacksonville

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2006-04
Est. Completion 2016-05-09
Phase NA
Mayo Clinic

2,844 total trials

What the finished NCT00436917 record still lists

NCT00436917 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which zoledronic acid is the first listed.

NCT00436917 reports a single indexed study location in Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT00436917 about?

NCT00436917 is a clinical study titled "Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer". RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women receiving letrozole for stage I, stage II, or stage IIIA primary breast c...

What is the current status of trial NCT00436917?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2006-04. Estimated completion is 2016-05-09.

What conditions does trial NCT00436917 study?

This clinical trial studies the following conditions: Breast Cancer, Osteoporosis.

What interventions are being tested in trial NCT00436917?

The interventions under investigation include: zoledronic acid (DRUG), Letrozole as adjuvant therapy (PROCEDURE).

Who is sponsoring clinical trial NCT00436917?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00436917 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00436917's enrollment target sits among peer trials

60 736th of 1224 higher than 468 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00436917, the US trial registry maintained by the National Library of Medicine. NCT00436917 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.